Core Insights - Pfizer reported strong Q4 2025 earnings with revenue of $17.6 billion, aligning closely with previous expectations of $18.1 billion, and adjusted net income of $3.8 billion, exceeding the prior forecast of $3.3 billion [2] - Total revenue for 2025 is projected at $62.6 billion, a 2% year-over-year decline, but operational revenue excluding COVID-19 products grew by 6%, indicating robust underlying business momentum [2] - The management reaffirmed guidance for 2026, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS ranging from $2.80 to $3.00, highlighting a year rich in catalysts [2] Company Analysis - Pfizer's pipeline includes significant catalysts such as long-acting GLP-1 and Amylin projects, with key data readouts expected in 2026 [2] - The VESPER-3 study demonstrated a 12.3% weight loss effect at the 28-week mark for the mid-dose group of PF'3944, with predictions suggesting a 15.8% weight loss for the high-dose group [6] - The company plans to initiate a Phase 3 study for PF'3944 later this year, with further updates on its obesity product portfolio expected [6][7] Market Performance - The Hang Seng Index closed at 26,847, reflecting a slight increase of 0.05% for the day and a year-to-date gain of 4.75% [2] - The U.S. stock market saw declines, particularly in technology and consumer discretionary sectors, while energy and materials sectors showed strength [4] - Notable movements included a 17% drop in AMD shares following weak guidance, impacting the semiconductor sector [4]

Investment Rating - The report maintains a "Buy" rating for Pfizer Inc. (PFE US) with a target price of $35.46, down from the previous target of $36.16, reflecting a potential upside of 32.4% from the current price of $26.78 [5][7]. Core Insights - Pfizer reported strong Q4 2025 results with revenues of $17.6 billion, aligning closely with the forecast of $18 billion. Adjusted net income was $3.8 billion, exceeding the estimate of $3.3 billion. Excluding COVID-19 products, operational revenue grew by 6% year-over-year, indicating a robust business foundation [3]. - The management reiterated revenue guidance for 2026 at $59.5 billion to $62.5 billion, with adjusted EPS projected between $2.80 and $3.00. Anticipated catalysts for 2026 include key data releases for long-acting GLP-1 and insulin projects, as well as positive clinical progress for obesity products and PF'4404 [3][5]. - The VESPER-3 study results for PF'3944 showed a 12.3% weight reduction at the medium dose, with expectations for the high dose to achieve a 15.8% reduction, positioning it competitively against alternatives [4]. - Pfizer is rapidly advancing the integration of PF'4404 (PD-1/VEGF) with its leading ADC product portfolio, aiming to establish a dominant position in the oncology market [5]. Financial Summary - For FY2026, revenue is projected at $60.7 billion, with a year-over-year decline of 2.9%. Adjusted net income is expected to be $16.34 billion, reflecting an 8.8% decrease from the previous year [6][16]. - The report outlines a decrease in P/E ratios, with FY2026 expected at 14.1x, down from 19.6x in FY2024, indicating a shift in valuation metrics [6][17]. - The DCF valuation estimates a share value of $35.46, based on a WACC of 9.95% and a terminal growth rate of 2.0% [13][14].

Market Performance - The Hang Seng Index closed at 26,847, with a slight increase of 0.05% for the day and a year-to-date increase of 4.75% [1] - The Hang Seng Technology Index decreased by 1.84% for the day and is down 2.71% year-to-date [1] - The US stock market saw the Dow Jones increase by 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51%, respectively [1] Sector Performance - In the Hong Kong market, the financial sector increased by 0.66% and is up 8.51% year-to-date, while the industrial sector decreased by 0.48% [2] - The real estate sector in Hong Kong saw a significant increase of 1.99% for the day and is up 17.13% year-to-date [2] Capital Flows - Southbound funds recorded a net inflow of 13.373 billion HKD, with Tencent, Alibaba, and Xiaomi being the top net buyers [3] - In contrast, SMIC, Hua Hong Semiconductor, and Jun Da Co. were the most sold stocks [3] US Market Trends - The US stock market experienced a sell-off in technology stocks, particularly in software and semiconductor sectors, with AMD's weak guidance leading to a 17% drop [3] - The S&P 500 software sector has seen an average decline of 25% since reaching a historical high last October [3] Company Analysis: Pfizer (PFE US) - Pfizer reported strong Q4 2025 earnings with revenue of 17.6 billion USD, slightly below the expected 18.1 billion USD, but adjusted net income exceeded expectations at 3.8 billion USD [4] - The company anticipates 2026 revenue between 59.5 billion to 62.5 billion USD, with adjusted EPS guidance of 2.80 to 3.00 USD [4] - Key upcoming milestones include data readouts for long-acting GLP-1 and Amylin projects, which are expected to drive significant valuation re-evaluation [4] Clinical Developments - Pfizer's VESPER-3 study showed a 12.3% weight loss effect at the 28-week mark for its long-acting GLP-1 candidate, with a potential 15.8% weight loss projected for a higher dose [5] - The company plans to initiate a Phase 3 study for the higher dose later this year, with detailed data expected at the ADA conference in June [5] Oncology Pipeline - Pfizer is advancing its PD-1/VEGF and ADC combination therapies, with ongoing Phase 3 trials for PF'4404 in colorectal cancer and additional trials planned for 2026 [6] - The market narrative is shifting towards pipeline execution strength, with obesity products and PF'4404 clinical progress expected to drive stock price increases [6]